244 related articles for article (PubMed ID: 29907679)
1. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
[TBL] [Abstract][Full Text] [Related]
2. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells.
Al Kafri N; Hafizi S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
[TBL] [Abstract][Full Text] [Related]
5. Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.
Khamko R; Wasenang W; Daduang J; Settasatian C; Limpaiboon T
In Vivo; 2022; 36(3):1168-1177. PubMed ID: 35478117
[TBL] [Abstract][Full Text] [Related]
6. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.
McKie AB; Vaughan S; Zanini E; Okon IS; Louis L; de Sousa C; Greene MI; Wang Q; Agarwal R; Shaposhnikov D; Wong JL; Gungor H; Janczar S; El-Bahrawy M; Lam EW; Chayen NE; Gabra H
Cancer Discov; 2012 Feb; 2(2):156-71. PubMed ID: 22585860
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.
Song X; Akasaka H; Wang H; Abbasgholizadeh R; Shin JH; Zang F; Chen J; Logsdon CD; Maitra A; Bean AJ; Wang H
J Biol Chem; 2020 Feb; 295(8):2348-2358. PubMed ID: 31959629
[TBL] [Abstract][Full Text] [Related]
8. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Hector A; Montgomery EA; Karikari C; Canto M; Dunbar KB; Wang JS; Feldmann G; Hong SM; Haffner MC; Meeker AK; Holland SJ; Yu J; Heckrodt TJ; Zhang J; Ding P; Goff D; Singh R; Roa JC; Marimuthu A; Riggins GJ; Eshleman JR; Nelkin BD; Pandey A; Maitra A
Cancer Biol Ther; 2010 Nov; 10(10):1009-18. PubMed ID: 20818175
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.
Antony J; Zanini E; Birtley JR; Gabra H; Recchi C
Cancer Gene Ther; 2021 Feb; 28(1-2):18-26. PubMed ID: 32595215
[TBL] [Abstract][Full Text] [Related]
10. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
[TBL] [Abstract][Full Text] [Related]
11. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.
Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H
J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175
[TBL] [Abstract][Full Text] [Related]
12. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1.
Tai KY; Shieh YS; Lee CS; Shiah SG; Wu CW
Oncogene; 2008 Jul; 27(29):4044-55. PubMed ID: 18345028
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
[TBL] [Abstract][Full Text] [Related]
14. A novel human anti-AXL monoclonal antibody attenuates tumour cell migration.
Duan Y; Luo L; Qiao C; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Scand J Immunol; 2019 Aug; 90(2):e12777. PubMed ID: 31075180
[TBL] [Abstract][Full Text] [Related]
15. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.
Fleuren ED; Hillebrandt-Roeffen MH; Flucke UE; Te Loo DM; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
Oncotarget; 2014 Dec; 5(24):12753-68. PubMed ID: 25528764
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression.
Umemura S; Sowa Y; Iizumi Y; Kitawaki J; Sakai T
Cancer Sci; 2020 Jun; 111(6):2052-2061. PubMed ID: 32291856
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
[TBL] [Abstract][Full Text] [Related]
18. Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis.
Sun LW; Kao SH; Yang SF; Jhang SW; Lin YC; Chen CM; Hsieh YH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831142
[TBL] [Abstract][Full Text] [Related]
19. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma.
Bae CA; Ham IH; Oh HJ; Lee D; Woo J; Son SY; Yoon JH; Lorens JB; Brekken RA; Kim TM; Han SU; Park WS; Hur H
Gastric Cancer; 2020 Sep; 23(5):824-836. PubMed ID: 32239298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
